Manipulation of immune regulation in systemic lupus erythematosus

被引:40
作者
La Cava, A [1 ]
Fang, CJ [1 ]
Singh, RP [1 ]
Ebling, F [1 ]
Hahn, BH [1 ]
机构
[1] Univ Calif Los Angeles, Div Rheumatol, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
systemic lupus erythematosus; immune regulation; immune suppression;
D O I
10.1016/j.autrev.2005.04.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Production of autoantibodies by B cells in systemic lupus erythematosus (SLE) can be interrupted via induction of regulatory and suppressor T cells. We have used the strategy of tolerizing lupus-prone (NZB x NZW)F-1 mice with an artificial peptide based on sequences common to several anti-double stranded (ds)DNA antibodies to induce regulatory and suppressor T cells that block production of anti-DNA antibodies and prolong their survival. At least one type of suppressor T cells (CD8(+)) and one type of regulatory T cell (CD4(+) expressing the IL-2 receptor a chain CD25) are raised Linder this condition. While CD8(+) suppressors (T-S) require soluble factors to block help of T cells to B cells, regulatory CD4(+)CD25(+) T cells (T-R) curb the production of anti-DNA antibodies from B cells via cell contact through molecules that include membrane-bound TGF beta and GITR. Moreover, CD8(+) suppressors seem to act independently on antigen specificity, while TR act in an antigen-specific fashion. We hypothesize that the differences between these two lymphocyte subsets that share the common ability to dampen production of autoantibodies might underlie significant temporal and teleological advantages for optimal control of autoimmune reactivity. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:515 / 519
页数:5
相关论文
共 29 条
  • [1] Signaling danger:: Toll-like receptors and their potential roles in kidney disease
    Anders, HJ
    Banas, B
    Schlöndorff, D
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (04): : 854 - 867
  • [2] IL-10-producing T regulatory type 1 cells and oral tolerance
    Battaglia, M
    Gianfrani, C
    Gregori, S
    Roncarolo, MG
    [J]. ORAL TOLERANCE: NEW INSIGHTS AND PROSPECTS FOR CLINICAL APPLICATION, 2004, 1029 : 142 - 153
  • [3] A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
    Boumpas, DT
    Furie, R
    Manzi, S
    Illei, GG
    Wallace, DJ
    Balow, JE
    Vaishnaw, A
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (03): : 719 - 727
  • [4] Interferon-α in systemic lupus erythematosus
    Crow, MK
    Kirou, KA
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (05) : 541 - 547
  • [5] Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
    Daikh, DI
    Wofsy, D
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (05) : 2913 - 2916
  • [6] Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1-and CDR3-based peptides of a pathogenic autoantibody
    Eilat, E
    Zinger, H
    Nyska, A
    Mozes, E
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (04) : 268 - 278
  • [7] CD4+ Tregs and immune control
    Fehérvari, Z
    Sakaguchi, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (09) : 1209 - 1217
  • [8] Filaci Gilberto, 2002, Autoimmunity Reviews, V1, P279, DOI 10.1016/S1568-9972(02)00065-4
  • [9] Hahn BH, 2001, ARTHRITIS RHEUM-US, V44, P432, DOI 10.1002/1529-0131(200102)44:2<432::AID-ANR62>3.0.CO
  • [10] 2-S